SOMERSET, N.J.— August 5, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, […]

First investigational product being recommended for Breakthrough Therapy Designation in China SOMERSET, NJ, August 5, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) announcedtoday that the China Center for Drug Evaluation, National Medical Products Administration(CDE, NMPA) has recommended Breakthrough Therapy Designation (BTD) for ciltacabtageneautoleucel (cilta-cel; LCAR-B38M CAR-T cells), an investigational B-cell maturation antigen(BCMA) targeted chimeric antigen […]